Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes.
The toxicity of a number of solubilized or colloidal amphotericin B formulations to human erythrocytes has been studied in-vitro. All the solubilized formulations studied, using poloxamer F127 or L92, or sodium deoxycholate as solubilizing agents, showed similar toxicity, erythrocyte lysis being greater than 90% for amphotericin B concentrations between 4 to 8 micrograms mL-1. Emulsion formulations stabilized by poloxamers showed reduced toxicity, while those stabilized by egg lecithin showed less than 5% erythrocyte lysis up to an amphotericin B concentration of 200 micrograms mL-1. The mechanisms of the differential toxicity is considered to be due to the differences in the equilibrium concentration of free amphotericin B in the aqueous phase.
D000328:Adult; D000666:Amphotericin B / Q000633:toxicity*; D003102:Colloids; D004912:Erythrocytes / Q000187:drug effects*; D006801:Humans; D008297:Male; D012995:Solubility
D003102:Colloids; D000666:Amphotericin B